| Literature DB >> 28892473 |
Cédric B Chesnais1, Naomi-Pitchouna Awaca-Uvon2, Fatoma K Bolay3, Michel Boussinesq1, Peter U Fischer4, Lincoln Gankpala3, Aboulaye Meite5, François Missamou6, Sébastien D Pion1, Gary J Weil4.
Abstract
BACKGROUND: The Global Programme to Eliminate Lymphatic Filariasis uses point-of-care tests for circulating filarial antigenemia (CFA) to map endemic areas and for monitoring and evaluating the success of mass drug administration (MDA) programs. We compared the performance of the reference BinaxNOW Filariasis card test (ICT, introduced in 1997) with the Alere Filariasis Test Strip (FTS, introduced in 2013) in 5 endemic study sites in Africa.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28892473 PMCID: PMC5608416 DOI: 10.1371/journal.pntd.0005703
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Characteristics and indicators of W. bancrofti endemicity levels in all the sites where ICT and FTS were used in parallel in subjects.
| Country | District | MDA | N | Median age | Males | No. ICT+ | No. FTS+ | FTS/ICT | No. | No. Mf+ | GM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Liberia | Total | IVM+ALB | 1,830 | 18 (10–40) | 51.1 | 285 (15.6) | 315 (17.2) | 1.11 | 2 | 41 (16.8) | 162.4 (102.2–257.9) |
| Foya | IVM+ALB | 681 | 14 (8–35) | 48.5 | 78 (11.5) | 81 (11.9) | 1.04 | 2 | 0 | NA | |
| Harper | IVM+ALB | 1,149 | 22 (10–42) | 52.6 | 207 (18.0) | 234 (20.4) | 1.13 | 0 | 41 (25.0) | 162.4 (102.2–257.9) | |
| Côte d'Ivoire | Lagunes | No | 968 | 29 (15–47) | 35.8 | 254 (26.2) | 263 (27.2) | 1.04 | 11 | 79 (30.4) | 227.8 (164.0–316.6) |
| Congo | Bouenza | ALB | 697 | 24 (10–43) | 46.7 | 44 (6.3) | 85 (12.2) | 1.93 | 1 | 10 (11.9) | 27.8 (13.4–57.5) |
| DRC | Kwilu | No | 187 | 15 (10–35) | 44.9 | 29 (15.5) | 42 (22.5) | 1.45 | 0 | 18 (42.9) | 302.2 (105.1–869.0) |
| Total Pre-MDA | - | 1,155 | 28 (14–45) | 37.3 | 283 (24.5) | 305 (26.4) | 1.08 | 11 | 97 (32.1) | 240.1 (173.9–331.5) | |
| Total Post-MDA | - | 2,527 | 20 (10–40) | 49.9 | 329 (13.0) | 400 (15.8) | 1.22 | 3 | 51 (15.6) | 114.8 (74.2–177.7) | |
| Total all sites | NA | 3,682 | 23 (11–42) | 45.9 | 612 (16.6) | 705 (19.2) | 1.15 | 14 | 148 (23.5) | 186.2 (143.2–242.2) | |
| Sri Lanka | DEC+ALB | 852 | 18 (2.1) | 43 (5.1) | 2.43 | 0 | - | - | |||
| Indonesia | DEC+ALB | 778 | 41 (5.3) | 50 (6.4) | 1.21 | 3 | - | - |
DRC = Democratic Republic of Congo; MDA = Mass Drug Administration; ALB = albendazole; IVM = ivermectin; N = number of subjects examined; IQR = Inter-quartile range; ICT+ = positive at the ICT test; FTS+ = positive at the FTS test; Mf+ = microfilaremic; GM = Geometric mean microfilarial density (Mf/mL) among the microfilaremic individuals; 95%CI = 95% Confidence Interval; NA = not applicable.
& Liberia, Côte d'Ivoire, Congo, and DRC (new data included in this paper); Sri Lanka and Indonesia (data already published) [9].
$ Four MDA rounds both for Liberia and Congo sites.
* Percentage of microfilaremic individuals and GM among those with positive FTS.
Cross-tabulation of filarial antigen test results (qualitative) obtained by the ICT and the FTS.
| Sites | No. of subjects according to ICT and FTS results | Indicators of agreement | ||||
|---|---|---|---|---|---|---|
| ICT+ | ICT- | Total | Percentage of agreement | Cohen's κ coefficient (95% CI) | ||
| Total pre-MDA sites | FTS+ | 272 | 33 | 305 | ||
| FTS- | 11 | 839 | 850 | 96.2 | 0.900 (0.871–0.929) | |
| Total | 283 | 872 | 1,155 | |||
| Côte d'Ivoire | FTS+ | 243 | 20 | 263 | ||
| FTS- | 11 | 694 | 705 | 96.8 | 0.918 (0.890–0.947) | |
| Total | 254 | 714 | 968 | |||
| DRC | FTS+ | 29 | 13 | 42 | ||
| FTS- | 0 | 145 | 145 | 93.1 | 0.776 (0.661–0.890) | |
| Total | 29 | 158 | 187 | |||
| Total post-MDA sites | FTS+ | 326 | 74 | 400 | ||
| FTS- | 3 | 2,124 | 2,127 | 97.0 | 0.877 (0.850–0.904) | |
| Total | 329 | 2,198 | 2,527 | |||
| Liberia Harper (IVM+ALB) | FTS+ | 283 | 32 | 315 | ||
| FTS- | 2 | 1,513 | 1,515 | 97.7 | 0.924 (0.896–0.952) | |
| Total | 285 | 1,545 | 1,830 | |||
| Liberia Foya (IVM+ALB) | FTS+ | 283 | 32 | 315 | ||
| FTS- | 2 | 1,513 | 1,515 | 99.0 | 0.950 (0.913–0.987) | |
| Total | 285 | 1,545 | 1,830 | |||
| Congo (ALB alone) | FTS+ | 43 | 42 | 85 | ||
| FTS- | 1 | 611 | 612 | 93.8 | 0.636 (0.538–0.735) | |
| Total | 44 | 653 | 697 | |||
Fig 1Cohen's Kappa score estimate obtained from a random-effects model.
LH: Liberia Harper District. LF: Liberia Foya District. CDI: Côte d'Ivoire. One village (Wetchoken, in the Harper district) from Liberia was not added in this analysis because all the ICT were negative. "RE model" represents the pooled Cohen's Kappa scores by group from the random-effects models.
Cross-tabulation of individual test scores obtained with the FTS and ICT.
| All sites Pre-MDA | Liberia Foya (Post-MDA) | ||||||||||
| ICT score | ICT score | ||||||||||
| 0 | 1 | 2 | 3 | Total | 0 | 1 | 2 | 3 | Total | ||
| FTS score | 0 | 839 | 6 | 4 | 1 | 850 | 598 | 7 | 0 | 0 | 599 |
| 1 | 30 | 1 | 0 | 105 | 3 | 2 | 0 | 20 | |||
| 2 | 3 | 75 | 1 | 124 | 1 | 3 | 2 | 28 | |||
| 3 | 0 | 6 | 30 | 76 | 1 | 0 | 2 | 33 | |||
| Total | 872 | 161 | 80 | 42 | 1,155 | 603 | 19 | 26 | 32 | 680 | |
| DRC (Pre-MDA) | Liberia Harper (Post-MDA) | ||||||||||
| ICT score | ICT score | ||||||||||
| 0 | 1 | 2 | 3 | Total | 0 | 1 | 2 | 3 | Total | ||
| FTS score | 0 | 145 | 0 | 0 | 0 | 145 | 917 | 0 | 0 | 0 | 917 |
| 1 | 11 | 0 | 0 | 13 | 28 | 2 | 0 | 121 | |||
| 2 | 2 | 5 | 0 | 7 | 0 | 41 | 0 | 99 | |||
| 3 | 0 | 5 | 13 | 22 | 0 | 0 | 6 | 12 | |||
| Total | 158 | 12 | 13 | 4 | 187 | 945 | 132 | 66 | 6 | 1,149 | |
| Côte d'Ivoire (Pre-MDA) | Congo (Post-MDA) | ||||||||||
| ICT score | ICT score | ||||||||||
| 0 | 1 | 2 | 3 | Total | 0 | 1 | 2 | 3 | Total | ||
| FTS score | 0 | 694 | 6 | 4 | 1 | 705 | 611 | 1 | 0 | 0 | 612 |
| 1 | 19 | 1 | 0 | 92 | 41 | 0 | 0 | 61 | |||
| 2 | 1 | 70 | 1 | 117 | 1 | 19 | 0 | 20 | |||
| 3 | 0 | 1 | 17 | 54 | 0 | 3 | 1 | 4 | |||
| Total | 714 | 149 | 67 | 38 | 968 | 653 | 43 | 1 | 0 | 697 | |
Results of the models exploring individual factors associated with ICT-miss (ICT-negative results in persons with positive FTS results).
| MDA history not included in the model | MDA history included in the model | ||||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | p-value | OR | 95% CI | p-value | ||
| Age (< 11 years old as reference) | 11–20 | 0.58 | 0.16–2.02 | 0.388 | 0.54 | 0.15–1.91 | 0.338 |
| 21–40 | 0.87 | 0.27–2.79 | 0.811 | 0.82 | 0.25–2.66 | 0.743 | |
| 41–60 | 0.77 | 0.23–2.59 | 0.672 | 0.74 | 0.22–2.50 | 0.627 | |
| >60 | 0.72 | 0.20–2.64 | 0.625 | 0.68 | 0.19–2.49 | 0.559 | |
| Sex (Female as reference) | Male | 0.90 | 0.54–1.49 | 0.678 | 0.91 | 0.55–1.51 | 0.716 |
| Positive | 0.16 | 0.06–0.40 | <0.001 | 0.16 | 0.06–0.39 | <0.001 | |
| Missing | 1.23 | 0.46–3.28 | 0.685 | 1.39 | 0.50–3.85 | 0.527 | |
| ICT prevalence in the village of residence (>30% as reference) | <10 | 26.73 | 4.02–177.58 | 0.001 | 37.05 | 5.26–360.8 | <0.001 |
| 10–20 | 6.50 | 1.05–40.21 | 0.044 | 5.94 | 0.96–36.89 | 0.056 | |
| 20–30 | 2.20 | 0.28–17.57 | 0.456 | 3.04 | 0.37–24.86 | 0.299 | |
| History of MDA in the village of residence (No MDA as reference) | Yes | NA | NA | NA | 0.20 | 0.03–1.38 | 0.101 |
| Intraclass correlation from district (2nd level) | 13.8% | 0.225 | 6.3% | 0.425 | |||
| 21.0% | <0.001 | 23.6% | <0.001 | ||||
Fig 2Relationship between the ICT prevalence rate and the FTS/ICT ratio.
All the data were included in this figure: Liberia (Foya and Harper), Côte d'Ivoire (Soribadougou and Yadio), Congo, DRC, Sri Lanka, and Indonesia (see Table 1 for details). Foya and Harper study areas comprised 9 and 15 villages, respectively. Black symbols (post-MDA IVM+ALB), blue symbols (post-MDA DEC+ALB), green symbol (post-MDA ALB alone), and pink symbols (pre-MDA).
Results for antigenemia and microfilaremia according to age class and history of MDA.
| No. tested | ICT | FTS | FTS/ICT ratio | No.TBS | Mf+ | ICT-/FTS+ | ICT+/FTS- | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. (%) | % Total pop. | No. | Mf+ | No. | Mf+ | |||||||
| All sites | 5–10 y.o. | 899 | 36 (4.0) | 40 (4.5) | 1.13 | 34 | 1 (2.9) | 0.1 | 5 | 0 | 1 | 0 |
| >10 y.o. | 2,783 | 576 (20.7) | 665 (23.9) | 1.15 | 608 | 151 (24.8) | 5.4 | 102 | 6 | 13 | 4 | |
| Pre-MDA | 5–10 y.o. | 160 | 7 (4.4) | 9 (5.6) | 1.27 | 9 | 1 (11.1) | 0.6 | 2 | 0 | 0 | 0 |
| >10 y.o. | 995 | 276 (27.7) | 296 (29.8) | 1.08 | 303 | 100 (33.0) | 10.1 | 31 | 1 | 11 | 4 | |
| Post-MDA | 5–10 y.o. | 739 | 29 (3.9) | 31 (4.2) | 1.08 | 25 | 0 | 0 | 3 | 0 | 1 | 0 |
| >10 y.o. | 1,788 | 300 (16.8) | 369 (20.6) | 1.23 | 305 | 51 (16.7) | 2.9 | 71 | 5 | 2 | 0 | |
* All the FTS were scored at 1. Eleven missing blood smears on the 107 ICT-/FTS+ individuals, from Soribadougou (Côte d'Ivoire) (2), and Foya (1) and Harper (8) districts (Liberia).
& On the 4, two ICT were scored at 1, one at 2, and one at 3. Two missing blood smears on the 14 ICT+/FTS- individuals, from Soribadougou (Côte d'Ivoire), and Foya district (Liberia).
# Number of positive tests and percentage.
Fig 3Probability of microfilaremia by CFA score.
The lines indicate the probabilities in the pre-MDA sites, and the dashed lines the probabilities in the post-MDA sites with 95% confidence intervals.